

Aether Catalyst Solutions, Inc.

MANAGEMENT'S DISCUSSION AND ANALYSIS Period ended September 30, 2021

GENERAL

This management's discussion and analysis ("MD&A") of financial position and the results of operations is prepared as at November 22, 2021, and should be read in conjunction with the condensed interim financial statements of Aether Catalyst Solutions Inc. ("the Company") for the period ended September 30, 2021 and 2020 and related notes thereto.

These condensed interim financial statements were prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). All dollar amounts included therein and in the following MD&A are in Canadian dollars except where noted. These documents and other information relevant to the Company's activities are available for viewing on SEDAR at www.sedar.com.

FORWARD-LOOKING STATEMENTS

Certain statements contained in this MD&A may constitute "forward-looking statements". Such term is defined in applicable securities laws. The forward-looking information includes, without limitation, the success of research and development activities and other similar statements concerning anticipated future events, conditions or results that are not historical facts. These statements reflect management's current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking information is inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among others, risks relating to research and development; the Company's intellectual property applications being approved, the Company's ability to protect its proprietary rights from unauthorized use or disclosure, the ability of the Company to obtain additional financing; the Company's limited operating history; the need to comply with environmental and governmental regulations; fluctuations in currency exchange rates; operating hazards and risks; competition; and other risks and uncertainties. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. All statements are made as of the Report Date and, except as required by law, the Company is under no obligation to update or alter any forward-looking information.

In March 2020, there was a global pandemic outbreak of COVID-19. The actual and threatened spread of the virus globally has had a material adverse effect on the global economy and specifically, the regional economies in which the Company operates. The pandemic could continue to have a negative impact on the stock market, including trading prices of the Company's shares and its ability to raise new capital. These factors, among others, could have a significant impact on the Company's operations.

DESCRIPTION OF BUSINESS

Aether Catalyst Solutions, Inc. (“Aether” or the “Company”) was incorporated under the British Columbia Business Corporations Act (“BCBCA”) on July 8, 2011.

The Company is a research and development company that is engaged in the development and potential subsequent commercialization of catalytic materials, initially for use in gasoline engine emissions abatement (automotive and small motors applications), but with other possible applications (including, for instance, diesel and volatile organic compounds).

The catalytic converter is effective at reducing automotive emissions, but that performance comes at a cost. Generally, the catalytic converters that have been developed to date utilize expensive materials, including precious metals and rare earth metals. In order to continue to meet escalating emissions standards, absent further and more cost-effective technologies, the only route is to increase the loading of these materials. These expensive materials increase the cost of catalytic converters to the extent that they have become a significant cost component of vehicles.

The Company has developed a low-cost, high-performance three-way catalyst to replace the more costly precious metal-based catalysts used in today’s automotive catalytic converters, and as an affordable solution to the significant emissions generated by unregulated small motors. The Company’s innovative technology does not contain any platinum, palladium, or Rhodium. Further, the Company has third party testing to validate internal performance tests of its catalysts.

The Company’s technology makes use of inexpensive base metals. Base metal catalysts typically have a lower activity than precious metals and are more susceptible to hydrothermal instability when exposed to the severe environment of the automobile’s exhaust. Atypically, the Company’s catalysts are active and stable at high temperatures.

The Company’s technology has been developed to overcome the aging robustness issues that are typically seen in other low-cost catalyst technology. Specifically, the Company has tested hundreds of sub-scale catalyzed plugs and has developed a unique formulation that allows for aging temperatures of up to 900 C in a range of environments.

While the Company’s primary activities currently involve conducting research, the Company’s objective is to enter into a joint development with an OEM or a major supplier, the terms and conditions of which would be set out in a joint development agreement. While the Company has not at this time entered into any such agreement, it is the Company’s ultimate goal to secure such a relationship and the Company hopes that entering into such an arrangement will help with attracting future funding in the form of grant money. If the Company is able to enter into such an arrangement, it anticipates that commercialization of its technology would follow.

The Company does not intend to manufacture products as its business model is to license its technology to entities that the Company believes may benefit from the technology, in exchange for royalty payments. In order to pursue this, the Company reaches out to and works with large OEMs and suppliers and as noted above, hopes to enter into a joint development agreement with an OEM in the future as it continues to refine its technology.

In October 2021, the Company entered into a Non-Disclosure Agreement (the “NDA”) with a large US fleet operator (“Fleetco”) to begin the evaluation and development of the Company’s catalyst for use in their fleet of over 150,000 vehicles. The Company expects to ship its first samples to Fleetco for testing during the 4th quarter.

OVERALL PERFORMANCE

The Company has no revenues, so its ability to ensure continued operations is its ability to obtain the necessary funding to complete development of its base metal catalytic material.

The head and registered offices of the Company are located at Unit 104, 8337 Eastlake Drive, Burnaby, British Columbia, V5A 4W2.

QUARTERLY INFORMATION

Quarter Ended	2021	2021	2021	2020
	September 30	June 30	March 31	December 31
Total assets	\$ 879,231	\$ 854,382	\$ 255,651	\$ 292,094
Working capital (deficit)	591,945	415,852	(209,231)	(171,240)
Net loss for the quarter	(111,469)	(98,090)	(125,880)	(37,254)
Net loss per share (Basic and diluted)	(0.00)	(0.00)	(0.00)	(0.00)

Quarter Ended	2020	2020	2020	2019
	September 30	June 30	March 31	December 31
Total assets	\$ 222,646	\$ 269,826	\$ 278,953	\$ 393,145
Working capital (deficit)	(122,016)	(204,762)	(128,416)	29,760
Net income (loss) for the quarter	(105,530)	(125,697)	(158,054)	(392,460)
Net income (loss) per share (Basic and diluted)	(0.00)	(0.00)	(0.00)	(0.01)

RESULTS OF OPERATIONS

Nine Months Ended September 30, 2021

During the nine months ended September 30, 2021, the Company recorded a net loss of \$335,439 (2020 - \$389,281). Significant fluctuations include the following:

- i) Amortization increased to \$50,262 (2020 - \$36,091) primarily as a result of an increase in additions to property, plant and equipment during the current period.
- ii) Consulting fees decreased to \$69,560 (2020 - \$86,170) primarily as a result of decreased consulting services incurred during the current period.
- iii) Interest and accretion decreased to \$13,424 (2020 - \$19,903) due to accretion of interest from the right-of-use assets.
- iv) Office expenses decreased to \$51,080 (2020 - \$110,443) due to the company conducting a buildout of office and lab space during the prior period.
- v) Professional fees increased to \$28,226 (2020 - \$17,631) primarily as a result of increased audit fees during the current period.

- vi) Share-based compensation increased to \$81,600 (2020 - \$Nil) as the result of new stock options granted and vested in the current period.
- vii) Wages and benefits decreased to \$125,721 (2020 - \$232,291) as a result of their being fewer employees during the period.
- viii) Grants and government tax credit decreased to \$102,245 (2020 - \$118,664) as the result of a new IRAP program (effective October 2018) and higher 2018 and 2019 stub year SRED credit received during the comparative period.

Three Months Ended September 30, 2021

During the three months ended September 30, 2021, the Company recorded a net loss of \$111,469 (2020 - \$105,530). Significant fluctuations include the following:

- i) Amortization increased to \$18,560 (2020 - \$12,201) primarily as a result of an increase in additions to property, plant and equipment during the current period.
- ii) Consulting fees increased to \$39,560 (2020 - \$15,000) primarily as a result of increased consulting services incurred during the current period.
- iii) Interest and accretion decreased to \$4,385 (2020 - \$8,178) due to accretion of interest from the right of-use assets
- iv) Office expenses decreased to \$19,410 (2020 - \$31,013) due to costs associated with lab and office renovations occurring during the prior period.
- v) Filing fees increased to \$5,830 (2020 - \$2,421) as the result of the private placement closed during the current period.
- vi) Wages and benefits decreased to \$48,641 (2020 - \$76,065) as a result of having fewer employees during the current period.

LIQUIDITY AND CAPITAL RESOURCES AND GOING CONCERN

Working capital at September 30, 2021, was \$591,945 (December 31, 2020 - capital deficiency of \$171,240). This was primarily a result of the Company's operating expenses and private placement proceeds received during the current year.

The financial statements were prepared using accounting policies consistent with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"), with the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business rather than through a process of forced liquidation for the foreseeable future. The operations of the Company were primarily funded by the issue of share capital and loans. The continued operations of the Company are dependent on its ability to develop a sufficient financing plan, receive continued financial support from related parties and lenders, complete sufficient public equity financing, or generate profitable operations in the future. These financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the company be unable to continue in business.

The Company is in the business of research and development that by its nature involves a high degree of risk. There can be no assurance that the Company's business and strategy will enable it to become profitable or sustain profitability in future periods. The Company's information technology systems are subject to disruption, damage or failure from a number of sources. This may result in a material adverse effect on the Company's business, financial condition, results of operations, cash flows or prospects. Additionally, the Company estimates that it will need additional capital to operate for the upcoming year. These material uncertainties may cast significant doubt on the Company's ability to continue as a going concern.

During the period from January 1, 2021, to November 22, 2021, the Company:

- i) completed a first tranche of its non-brokered private placement and issued 4,169,550 units at a price of \$0.175 per unit for gross aggregate proceeds of \$729,671. Each unit consists of one common share and one common share purchase warrant exercisable at \$0.225 for a period of 24 months.

The Company paid finder's fees of \$57,709 and issued 400,947 finders' warrants (valued at \$54,700), entitling the holder thereof to purchase one unit of the Company at a price of \$0.175 per warrant share for a period of 24 months. Each unit will consist of one common share and one common share purchase warrant exercisable at \$0.225 for a period of 24 months.

- ii) completed the final tranche of its non-brokered private placement and issued 1,990,500 units at a price of \$0.175 per unit for gross aggregate proceeds of \$348,338. Each unit consists of one common share and one common share purchase warrant exercisable at \$0.225 for a period of 24 months.

The Company paid finder's fees of \$26,467 and issued 189,050 finders' warrants (valued at \$41,700), entitling the holder thereof to purchase one unit of the Company at a price of \$0.175 per warrant share for a period of 24 months. Each unit will consist of one common share and one common share purchase warrant exercisable at \$0.225 for a period of 24 months.

- iii) issued 100,000 shares for total proceeds of \$22,500 for warrants exercised.

- iv) issued 95,725 units for total proceeds of \$16,752 for broker warrants exercised. Each unit consists of a common share and a warrant exercisable at a price of \$0.225 for a period of 24 months.

OFF-BALANCE SHEET ARRANGEMENTS

There are no off-balance sheet arrangements or obligations that are not disclosed in the financial statements.

RELATED PARTY TRANSACTIONS

	Period ended September 30, 2021	Period ended December 31, 2020
Transactions with Key Management Personnel		
Consulting fees paid to a director, officers, a company with common directors and a company owned by a director and officer	\$ 45,000	\$ 15,000
Wages paid/accrued to officers	\$ 46,500	\$ 25,000
Share-based compensation to directors and officers	\$ 66,489	\$ -

As at September 30, 2021, accounts payable and accrued liabilities include \$15,768 (December 31, 2020 – \$77,296) owing to a company owned by a director, officers and companies with common directors. The amounts are unsecured, non-interest bearing and have no specific terms of repayment.

As at September 30, 2021, other receivable includes \$3,450 (December 31, 2020 – \$24,688) owing from a director and companies with common directors. The amounts are unsecured, non-interest bearing and have no specific terms of repayment.

As at September 30, 2021, loans payable included \$15,015 (December 31, 2020 – \$15,015) owing to a director and companies with common directors.

CHANGES IN ACCOUNTING STANDARDS

Please refer to the September 30, 2021, condensed interim financial statements on www.sedar.com for accounting policy pronouncements.

FINANCIAL INSTRUMENTS

Financial Risk Management

The Company's financial instruments consist of cash, accounts payable and accrued liabilities and loans payable. Unless otherwise noted, it is management's opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments. The fair values of these financial instruments approximate their carrying values, unless otherwise noted. See Note 9 of the Company's financial statements for the period ended September 30, 2021, for a discussion of the Company's risk exposure and the impact thereof on the Company's financial instruments.

The Company's cash at September 30, 2021, was \$693,034 and was primarily held at a major Canadian financial institution. The Company does not believe it is exposed to significant currency risk as funds are held in Canadian currency and there are no significant foreign exchange currency transactions. The Company does not use any derivative instruments to reduce its exposure to fluctuations in foreign currency exchange rates.

RISKS AND UNCERTAINTIES

An investment in the common shares of the Company should be considered highly speculative due to the nature of the business of the Company, consisting of research, development and commercialization of patents for industrial products, as well the Company's present stage of its development and its lack of

operating history. In evaluating the business of the Company, readers should carefully consider the following risk factors. Additional risks not currently known to the Company as of the date hereof may also impair future business operations of Company. The list below is not a definitive list of all risk factors associated with the business of the Company.

Management and directors

The Company's management may not be successful in managing the business of the Company. Further, management is under no contractual obligation to remain with the Company and the departure of members of management could cause the business to fail. The Company is dependent on the services of directors and officers who have varied business interests and are involved with other companies. No member of management has signed a written employment agreement with the Company, and it may not always be possible to pay management at industry-competitive rates. In the event that any or all of the Company's directors and officers decide to resign, the Company may be unable to attract other qualified officers or directors, and their departure could cause the business to fail.

The Company's business is also dependent on retaining the services of a small number of key personnel of the appropriate caliber as the business develops. The future success of the Company will, to a significant degree, be reliant upon the retention of such key personnel.

Current global financial conditions may adversely impact the Company and the value of the Common Shares

Current global financial conditions have been subject to increased volatility and numerous financial institutions have either gone into bankruptcy or have had to be rescued by governmental authorities. Access to public financing has been negatively impacted by both the credit market crisis and the liquidity crisis affecting the asset-backed commercial paper market. These factors may impact the ability of the Company to obtain equity or debt financing in the future and, if obtained, on terms favourable to the Company. If these increased levels of volatility and market turmoil continue, the Company's operations could be adversely impacted, and the value of the Common Shares could be adversely affected.

Dilution

Common Shares, as well as rights, warrants, special warrants, subscription receipts and other securities to purchase, to convert into or to exchange into Common Shares, may be created, issued, sold and delivered on such terms and conditions and at such times as the Board may determine. In addition, the Company may issue additional Common Shares from time to time pursuant to share purchase warrants and the options to purchase Common Shares issued from time to time by the Board. The issuance of Common Shares could result in dilution to existing security holders.

Future sales by existing shareholders could cause the Company's share price to fall

Future sales of Common Shares by the Company or other shareholders could decrease the value of the Common Shares. The Company cannot predict the size of future sales by the Company or other shareholders, or the effect, if any, that such sales will have on the market price of the Common Shares. Sales of a substantial number of Common Shares, or the perception that such sales could occur, may adversely affect prevailing market prices for the Common Shares.

Profitability of the Company

There can be no assurance that the Company's business and strategy will enable it to become profitable or sustain profitability in future periods. The Company's future operating results will depend on various factors, many of which are beyond the Company's direct control, including the Company's ability to control its costs and general economic conditions. If the Company is unable to generate profits in the future, the market price of the Common Shares could decline.

Litigation

All industries, including the research and development industry, are subject to legal claims, with and without merit. Legal proceedings may arise from time to time in the course of the Company's business. Such litigation may be brought from time to time in the future against the Company. Defense and settlement costs of legal claims can be substantial, even with respect to claims that have no merit. Other than as disclosed elsewhere in this Prospectus, the Company is not currently subject to material litigation nor has the Company received an indication that any material claims are forthcoming. However, due to the inherent uncertainty of the litigation process, the Company could become involved in material legal claims or other proceedings with other parties in the future. The results of litigation or any other proceedings cannot be predicted with certainty. The cost of defending such claims may take away from management's time and effort and if the Company is incapable of resolving such disputes favourably, the resultant litigation could have a material adverse impact on the Company's financial condition, cash flow and results from operation.

Risks related to possible fluctuations in revenues and results

The Company may experience significant fluctuations in its quarterly and annual results of operations for a variety of reasons, many of which are outside of the Company's control. Any fluctuations may cause the Company's results of operations to fall below the expectations of securities analysts and investors. This would likely affect the ability of a purchaser to dispose of the Company's shares or the market price of the shares if trading of them is possible in a marketplace.

Negative cash flow from operations

During the period ended September 30, 2021, the Company had negative cash flow from operating activities. Although the Company anticipates it will have positive cash flow from operating activities in future periods, to the extent that the Company has negative cash flow in any future period, it will need to raise additional funds to cover this shortfall.

Going concern risk

Our registered independent auditors have issued an opinion on our financial statements as of September 30, 2021, which includes a statement describing our going concern status. This means that there is substantial doubt that we can continue as an ongoing business for the next twelve months unless we obtain additional capital to pay our bills and meet our other financial obligations. This is because we have not generated any revenues and no revenues are anticipated until we begin to license our proprietary technology for royalty payments.

In addition to cash flow from operations, ongoing operations may be dependent on the Company's ability to obtain equity financing by the issuance of capital and to generate profitable operations in

the future. Significant amounts of capital expenditures are required in order for the Company to execute its business plan and there are no assurances that the Company will have sufficient funds for this purpose.

Fluctuation and volatility in stock exchange prices

The market price of a publicly traded stock is affected by many variables, including the availability and attractiveness of alternative investments and the breadth of public market for the stock. In recent years, the securities markets have experienced a high level of price and volume volatility, and the market prices of securities of many companies have experienced wide fluctuations in price which have not necessarily been related to the operating performance, underlying asset values or prospects of such companies.

For instance, the market price for the Common Shares may be volatile and subject to wide fluctuations in response to numerous factors, many of which are beyond our control, including the following:

- actual or anticipated fluctuations in our quarterly results of operations;
- recommendations by securities research analysts;
- changes in the economic performance or market valuations of companies in the industry in which we operate;
- addition or departure of our executive officers and other key personnel;
- release or expiration of lock-up or other transfer restrictions on outstanding Common Shares;
- sales or perceived sales of additional Common Shares;
- significant acquisitions or business combinations, strategic partnerships, joint ventures or capital commitments by or involving us or our competitors;
- operating and share price performance of other companies that investors deem comparable to us;
- changes in global financial markets and global economies and general market conditions;
- operating and share price performance of other companies that investors deem comparable to the Company or from a lack of market comparable companies; and
- news reports relating to trends, concerns, technological or competitive developments, regulatory changes and other related issues in our industry or target markets.

Financial markets have recently experienced significant price and volume fluctuations that have particularly affected the market prices of equity securities of companies and that have often been unrelated to the operating performance, underlying asset values or prospects of such companies. Accordingly, the market price of the Common Shares may decline even if our operating results, underlying asset values or prospects have not changed. Additionally, these factors, as well as other related factors, may cause decreases in asset values that are deemed to be other than temporary, which might result in impairment losses. There can be no assurance that continuing fluctuations in price and volume will not occur. If such increased levels of volatility and market turmoil continue,

our operations could be adversely affected, and the trading price of the Common Shares might be materially adversely affected.

Further, there can be no assurance that such variations will not affect the price of the Company's securities in the future.

Market for the Company's securities

There has been a limited public trading market for the Common Shares. There can be no guarantee that an active and liquid trading market will develop or be maintained, the failure of which may have a material adverse effect on the value of the Common Shares and the ability of a purchaser to dispose of the Common Shares in a timely manner, or at all. In addition, the market price of the securities of the Company at any given point in time may not accurately reflect the long-term value of the Company.

Limited operating history

The Company is subject to all of the business risks and uncertainties associated with any early-state enterprise, including under-capitalization, cash shortages, limitations with respect to personnel, financial and other resources and lack of revenues.

Additional financing

The Company expects that it will require equity and/or debt financing to support ongoing operations, to undertake capital expenditures or to undertake acquisitions or other business combination transactions. There can be no assurance that additional financing will be available to the Company when needed or on terms which are acceptable. The Company's inability to raise financing to fund on-going operations, capital expenditures or acquisitions could limit its growth and may have a material adverse effect upon the Company's business, results of operations, financial condition or prospects.

If additional funds are raised through further issuances of equity or convertible debt securities, existing shareholders could suffer significant dilution, and any new equity securities issued could have rights, preferences and privileges superior to those of holders of Common Shares. Any debt financing secured in the future could involve restrictive covenants relating to capital raising activities and other financial and operational matters, which may make it more difficult for the Company to obtain additional capital and to pursue business opportunities, including potential acquisitions.

Ongoing costs and obligations

The Company expects to incur significant ongoing costs and obligations related to its investment in infrastructure and growth and for regulatory compliance, which could have a material adverse impact on the Company's results of operations, financial condition and cash flows. In addition, unanticipated events could require extensive changes to the Company's operations, increased compliance costs or give rise to material liabilities, which could have a material adverse effect on the business, results of operations and financial condition of the Company.

Competition

There is potential that the Company will face intense competition from other companies, some of which can be expected to have longer operating histories and more financial resources and experience than the Company. Increased competition by larger and better financed competitors could materially and adversely affect the business, financial condition, results of operations or prospects of the Company.

Product approvals

The Company may require advance approval of its products from federal, provincial and/or local authorities. There is no guarantee that such products will be approved to the extent necessary. If the products are approved, there is a risk that any federal, provincial and/or local jurisdiction may revoke its approval for such products based on changes in laws or regulations or based on its discretion or otherwise. If any of the Company's products are not approved or any existing approvals are rescinded, there is the potential to lead to a material adverse effect on the Company's business, financial condition, results of operations or prospects.

Research and development

Before the Company can obtain regulatory approval for the commercial sale of any of its licenses, it will be required to complete extensive trial testing to demonstrate safety and efficacy. Depending on the exact nature of trial testing, such trials can be expensive and are difficult to design and implement. The testing process is also time consuming and can often be subject to unexpected delays.

The timing and completion of trial testing may be subject to significant delays relating to various causes, including: inability to manufacture or obtain sufficient quantities of units and or test subjects for use in trial testing; delays arising from supporting relationships; delays in obtaining regulatory approvals to commence a study, or government intervention to suspend or terminate a study; delays, suspensions or termination of trial testing due to the applicable institutional review board or independent ethics board responsible for overseeing the study to protect research subjects; delays in identifying and reaching agreement on acceptable terms with prospective trial testing sites and subjects; variability in the number and types of subjects available for each study and resulting difficulties in identifying and enrolling subjects who meet trial eligibility criteria; scheduling conflicts; difficulty in maintaining contact with subjects after testing, resulting in incomplete data; unforeseen safety issues or side effects; lack of efficacy during trial testing; reliance on research organizations to conduct trial testing, which may not conduct such trials with good laboratory practices; or other regulatory delays.

Difficulty in developing products

If the Company cannot successfully develop its products, the Company may not be able to sell product licenses for royalty payments, which would adversely affect the Company's ability to effectively enter the market.

Success of new and existing products and services

The Company has committed, and expects to continue to commit, significant resources and capital to develop and market its existing product license and new product licenses. The Company's

technology is relatively untested, and the Company cannot guarantee that it will achieve market acceptance for the technology, or other new technology that it may offer in the future. Moreover, the Company's technology may be subject to significant competition with offerings by new and existing competitors in the business similar to that of the Company. In addition, new products, services and enhancements may pose a variety of technical challenges and require the Company to attract additional qualified employees. The failure to successfully develop and market these new technology or new products or to hire qualified employees could seriously harm the Company's business, financial condition and results of operations.

Continued market acceptance by large OEMs and suppliers

The Company is substantially dependent on continued market acceptance of its technology by large OEMs and suppliers. The Company cannot predict the future growth rate and size of this market.

Director and officer control of Common Shares

The officers and directors of the Company currently hold (directly or indirectly) approximately 15.5% of the issued and outstanding Common Shares. In addition, 30.7% of the issued and outstanding Common Shares are held by Conation Capital Corp., which Paul Woodward is the President of. The Company's shareholders nominate and elect the Board, which generally has the ability to control the acquisition or disposition of the Company's assets, and the future issuance of its Common Shares or other securities. Accordingly, for any matters with respect to which a majority vote of the Common Shares may be required by law, the Company's directors and officers may have the ability to control such matters. Because the directors and officers control a substantial portion of such Common Shares, investors may find it difficult or impossible to replace the Company's directors if they disagree with the way the Company's business is being operated.

Difficulty to forecast

The Company must rely largely on its own market research to forecast sales as detailed forecasts are not generally obtainable from other sources at this early stage of the industry. A failure in the demand for its technology licenses to materialize as a result of competition, technological change or other factors could have a material adverse effect on the business, results of operations, financial condition or prospects of the Company.

Management of growth

The Company may be subject to growth-related risks including capacity constraints and pressure on its internal systems and controls. The ability of the Company to manage growth effectively will require it to continue to implement and improve its operational and financial systems and to expand, train and manage its employee base. The inability of the Company to deal with this growth may have a material adverse effect on the Company's business, financial condition, results of operations or prospects.

Internal controls

Effective internal controls are necessary for the Company to provide reliable financial reports and to help prevent fraud. Failure to implement required new or improved controls, or difficulties encountered in their implementation, could harm the Company's results of operations or cause it to

fail to meet its reporting obligations. If the Company or its auditors discover a material weakness, the disclosure of that fact, even if quickly remedied, could reduce the market's confidence in the Company's consolidated financial statements and materially adversely affect the trading price of the Common Shares.

Conflicts of interest

Certain of the directors and officers of the Company are, or may become directors and officers of other companies, and conflicts of interest may arise between their duties as officers and directors of the Company and as officers and directors of such other companies.

Intellectual property risks

The Company has certain proprietary intellectual property, has applied for additional intellectual property and may seek protection for additional intellectual property in the future. The Company will rely on this intellectual property, know-how and other proprietary information, and may require employees, consultants and suppliers to sign confidentiality agreements. However, any confidentiality agreement may be breached, and the Company may not have adequate remedies for such breaches. Third parties may independently develop substantially equivalent proprietary information without infringing upon any proprietary technology. Third parties may otherwise gain access to the Company's proprietary information and adopt it in a competitive manner. Any loss of intellectual property protection may have a material adverse effect on the Company's business, results of operations or prospects.

Fraudulent or illegal activity by employees, contractors and consultants

The Company is exposed to the risk that its employees, independent contractors and consultants may engage in fraudulent or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to the Company that violates: (i) government regulations; (ii) manufacturing standards; (iii) federal and provincial healthcare fraud and abuse laws and regulations; or (iv) laws that require the true, complete and accurate reporting of financial information or data. It may not always be possible for the Company to identify and deter misconduct by its employees and other third parties, and the precautions taken by the Company to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting the Company from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against Company, and it is not successful in defending itself or asserting its rights, those actions could have a significant impact on the Company's business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of the Company's operations, any of which could have a material adverse effect on the Company's business, financial condition, results of operations or prospects.

Operating risks and insurance

The Company's operations are subject to hazards inherent in its industry, such as equipment defects, malfunction and failures, natural disasters which result in fires, accidents and explosions that can cause personal injury, loss of life, suspension of operations, damage to facilities, business interruption and damage to or destruction of property, equipment and the environment, labour

disputes, and changes in the regulatory environment. These risks could expose the Company to substantial liability for personal injury, wrongful death, property damage, pollution, and other environmental damages. The frequency and severity of such incidents will affect operating costs, insurability and relationships with customers, employees and regulators.

The Company continuously monitors its operations for quality control and safety. However, there are no assurances that the Company's safety procedures will always prevent such damages. Although the Company maintains insurance coverage that it believes to be adequate and customary in the industry, there can be no assurance that such insurance will be adequate to cover its liabilities. In addition, there can be no assurance that the Company will be able to maintain adequate insurance in the future at rates it considers reasonable and commercially justifiable. The occurrence of a significant uninsured claim, a claim in excess of the insurance coverage limits maintained by the Company, or a claim at a time when it is not able to obtain liability insurance, could have a material adverse effect on the Company, the Company's ability to conduct normal business operations and on the Company's business, financial condition, results of operations and cash flows in the future.

Uninsured or uninsurable risk

The Company may be subject to liability for risks against which it cannot insure or against which the Company may elect not to insure due to the high cost of insurance premiums or other factors. The payment of any such liabilities would reduce the funds available for the Company's normal business activities. Payment of liabilities for which the Company does not carry insurance may have a material adverse effect on the Company's financial position and operations.

Issuance of debt

From time to time, the Company may enter into transactions to acquire assets or the shares of other organizations. These transactions may be financed in whole or in part with debt, which may increase the Company's debt levels above industry standards for companies of similar size. Depending on future development plans, the Company may require additional equity and/or debt financing that may not be available or, if available, may not be available on favourable terms to the Company. Neither the Company's articles nor its by-laws limit the amount of indebtedness that the Company may incur. As a result, the level of the Company's indebtedness from time to time, could impair its ability to obtain additional financing on a timely basis to take advantage of business opportunities that may arise.

Financial projections may prove materially inaccurate or incorrect

The Company's financial estimates, projections and other forward-looking information accompanying this Prospectus were prepared by the Company without the benefit of reliable historical industry information or other information customarily used in preparing such estimates, projections and other forward-looking information. Such forward-looking information is based on assumptions of future events that may or may not occur, which assumptions may not be disclosed in such documents. Investors should research the Company and become familiar with the assumptions underlying any estimates, projections or other forward-looking information. Projections are inherently subject to varying degrees of uncertainty and their achievability depends on the timing and probability of a complex series of future events. There is no assurance that the assumptions upon which these projections are based will be realized. Actual results may differ materially from projected results for a number of reasons including increases in operation expenses, changes or shifts

in regulatory rules, undiscovered and unanticipated adverse industry and economic conditions, and unanticipated competition. Accordingly, investors should not rely on any projections to indicate the actual results the Company might achieve.

Certain remedies and rights to indemnification may be limited

The Company's governing documents provide that the liability of its Board and officers is eliminated to the fullest extent allowed under the laws of British Columbia. Thus, the Company and the shareholders of the Company may be prevented from recovering damages for alleged errors or omissions made by the members of the Board and its officers. The Company's governing documents also provide that the Company will, to the fullest extent permitted by law, indemnify members of the Board and its officers for certain liabilities incurred by them by virtue of their acts on behalf of the Company.

OUTSTANDING SHARE DATA AT NOVEMBER 22, 2021

COMMON SHARES

There are 49,437,794 common shares issued and outstanding.

OPTIONS

The following options were outstanding at November 22, 2021:

Number of Options	Exercise Price	Expiry Date
1,350,000	\$0.10	January 8, 2023
1,150,000	\$0.20	November 28, 2024
2,500,000		

WARRANTS

The following warrants were outstanding, and exercisable into common shares, at November 22, 2021:

Number of Warrants	Exercise Price	Expiry Date
4,069,550	\$0.225	June 23, 2023
1,990,500	\$0.225	July 14, 2023
6,060,050		

BROKER WARRANTS

The following broker warrants were outstanding and exercisable into units at November 22, 2021. Each unit will consist of one common share and one common share purchase warrant exercisable at \$0.225 for a period of 24 months:

Number of Broker Warrants	Exercise Price	Expiry Date
381,747	\$0.175	June 23, 2023
112,525	\$0.175	July 14, 2023
14,400	\$0.225	October 28, 2023
4,800	\$0.225	November 10, 2023
76,525	\$0.225	November 17, 2023
589,997		